Skip to main content
. 2017 Nov 13;2017(52):lgx015. doi: 10.1093/jncimonographs/lgx015

Table 1.

Baseline characteristics of participants (n = 312)

High exposure No. (%) Low exposure No. (%) P*
Age, y
 Mean±SD 58.5±12.6 56.5±12.9 .18
Sex
 Male 94 (56.6) 81 (55.5) .84
 Female 72 (43.4) 65 (44.5)
Tumor location .21
 Rectum 81 (48.8) 61 (41.8)
 Colon 85 (51.2) 85 (58.2)
TNM stage .008
 II 92 (55.4) 59 (40.4)
 III 74 (44.6) 87 (59.6)
Chemotherapy regimen
 5-Fu+DDP 0 1 (0.7) .004
 FOLFIRI 1 (0.6) 0
 FOLFOX 76 (45.8) 48 (32.9)
 Mayo Clinic 0 1 (0.7)
 XELODA 7 (4.2) 3 (2.1)
 XELOX 14 (8.4) 5 (3.4)
 5-fu+CF+LOHP 9 (5.4) 7 (4.8)
 Unknown 3 (1.8) 1 (0.7)
 None 56 (33.7) 80 (54.8)
Stage and chemotherapy <.001
 II with chemo 51 (30.7) 29 (19.9)
 II without chemo 41 (24.7) 30 (20.5)
 III with chemo 59 (35.5) 37 (25.3)
 III without chemo 15 (9.0) 50 (34.2)
*

Chi-square test or Fisher’s exact test for categorical variables; t test for continuous variables.